title: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
abstract: BACKGROUND
  Secondary surgical cytoreduction (SCR) represents a promising therapeutic strategy for patients affected by ovarian cancer disease recurrence. The aim of this prospective observational trial was to analyze the role of SCR in patients with platinum-sensitive ovarian cancer.
  
  
  METHODS
  Patients with platinum-sensitive ovarian cancer underwent SCR by a single surgical team. Clinical and oncologic data were prospectively recorded. A total of 47 patients underwent SCR from 1999 to 2003.
  
  
  RESULTS
  The mean operating time was 210 minutes, and mean blood loss was 500 mL. The most frequent surgical procedures carried out were splenectomy, lymphadenectomy, bowel resection, and extensive peritonectomy. Optimal cytoreduction was achieved in 41 patients. Thirty-seven patients had no visible tumor at the end of SCR. Overall median survival was 49 months. Patients who achieved optimal residual disease had a median survival of 61 months, whereas patients who had residual disease >1 cm had a median survival of 19 months.
  
  
  CONCLUSIONS
  Positive CA-125 (cancer antigen 125) was identified as a negative prognostic factor at multivariate analysis. After careful selection, optimal cytoreduction can be achieved in most patients who are subjected to SCR with acceptable morbidity. Residual tumor and CA-125 represent the most important prognostic factors.
authors.affiliation: Department of Obstetrics and Gynecology, University of Rome La Sapienza, Viale del Policlinico, 155, 00161, Rome, Italy. pierluigi.benedettipanici@uniroma1.it
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Benedetti Panici
authors.forename: Antonio
authors.initials: A
authors.lastname: De Vivo
authors.forename: Filippo
authors.initials: F
authors.lastname: Bellati
authors.forename: Natalina
authors.initials: N
authors.lastname: Manci
authors.forename: Giorgia
authors.initials: G
authors.lastname: Perniola
authors.forename: Stefano
authors.initials: S
authors.lastname: Basile
authors.forename: Ludovico
authors.initials: L
authors.lastname: Muzii
authors.forename: Roberto
authors.initials: R
authors.lastname: Angioli
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D019370:Observation; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010984:Platinum / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D010984:Platinum